GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult population between the ages of 50 and 59 who are at higher ...

GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to expand the use of vaccines against the respiratory syncytial virus (RSV) for a broader population in ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY in adults aged 50-59 who ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

In addition to the RSV vaccine vote, the committee also recommended use of a new meningococcal vaccine from GSK, a chikungunya ... and vaccine development. Follow her on Mastodon and Bluesky.